 Irene Schauer
Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 16 | 2024 | 3952 | 1.010 |
Why?
| | Insulin Resistance | 13 | 2024 | 1253 | 0.940 |
Why?
| | Mitochondria, Muscle | 2 | 2024 | 125 | 0.870 |
Why?
| | Hyperinsulinism | 4 | 2022 | 115 | 0.860 |
Why?
| | Metabolic Syndrome | 4 | 2026 | 365 | 0.810 |
Why?
| | Hyperlipidemias | 3 | 2022 | 120 | 0.790 |
Why?
| | Luteinizing Hormone | 5 | 2026 | 207 | 0.760 |
Why?
| | Follicle Stimulating Hormone | 5 | 2026 | 266 | 0.720 |
Why?
| | Vascular Stiffness | 3 | 2024 | 488 | 0.690 |
Why?
| | Insulin | 10 | 2022 | 2526 | 0.580 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2021 | 154 | 0.510 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2024 | 2627 | 0.500 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2010 | 450 | 0.490 |
Why?
| | Cross-Over Studies | 6 | 2024 | 617 | 0.470 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2014 | 146 | 0.380 |
Why?
| | Diabetic Angiopathies | 4 | 2017 | 267 | 0.320 |
Why?
| | Lipoproteins, LDL | 1 | 2010 | 119 | 0.300 |
Why?
| | Muscle, Skeletal | 7 | 2024 | 1798 | 0.270 |
Why?
| | Exercise | 6 | 2024 | 2219 | 0.270 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 274 | 0.260 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2218 | 0.260 |
Why?
| | Fatty Acids | 1 | 2010 | 461 | 0.250 |
Why?
| | Bromocriptine | 2 | 2022 | 31 | 0.230 |
Why?
| | Atherosclerosis | 1 | 2010 | 411 | 0.230 |
Why?
| | Glucose Clamp Technique | 7 | 2021 | 199 | 0.230 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 268 | 0.220 |
Why?
| | Hypertension | 4 | 2010 | 1280 | 0.210 |
Why?
| | Adult | 27 | 2026 | 41405 | 0.210 |
Why?
| | Lipids | 5 | 2022 | 723 | 0.210 |
Why?
| | Diet, High-Fat | 1 | 2026 | 267 | 0.210 |
Why?
| | Young Adult | 10 | 2026 | 14437 | 0.210 |
Why?
| | Blood Glucose | 7 | 2024 | 2359 | 0.200 |
Why?
| | Adipose Tissue, Brown | 1 | 2024 | 60 | 0.200 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 94 | 0.190 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 165 | 0.190 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 75 | 0.190 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.180 |
Why?
| | Female | 30 | 2026 | 80076 | 0.180 |
Why?
| | Glycolysis | 1 | 2024 | 341 | 0.180 |
Why?
| | Case-Control Studies | 4 | 2024 | 3660 | 0.180 |
Why?
| | Oxygen | 2 | 2018 | 998 | 0.180 |
Why?
| | Human Growth Hormone | 1 | 2022 | 47 | 0.170 |
Why?
| | Signal Transduction | 2 | 2021 | 5272 | 0.170 |
Why?
| | Leg | 2 | 2021 | 243 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 627 | 0.170 |
Why?
| | Humans | 42 | 2026 | 147293 | 0.170 |
Why?
| | Resistance Training | 1 | 2024 | 186 | 0.170 |
Why?
| | Soybean Oil | 1 | 2021 | 15 | 0.170 |
Why?
| | Cyclins | 3 | 1997 | 79 | 0.160 |
Why?
| | Adolescent | 14 | 2024 | 22825 | 0.160 |
Why?
| | Incretins | 1 | 2020 | 21 | 0.160 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 212 | 0.160 |
Why?
| | Middle Aged | 19 | 2024 | 36821 | 0.160 |
Why?
| | Bone Remodeling | 1 | 2020 | 71 | 0.150 |
Why?
| | Bone Resorption | 1 | 2020 | 81 | 0.150 |
Why?
| | Dietary Fats | 3 | 2012 | 309 | 0.150 |
Why?
| | Obesity | 4 | 2023 | 3149 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2024 | 289 | 0.150 |
Why?
| | Male | 27 | 2024 | 73950 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.150 |
Why?
| | Retinoblastoma Protein | 2 | 2001 | 62 | 0.150 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.150 |
Why?
| | Glucose | 2 | 2024 | 1051 | 0.140 |
Why?
| | Diastole | 1 | 2019 | 147 | 0.140 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.140 |
Why?
| | Coronary Vessels | 2 | 2010 | 246 | 0.140 |
Why?
| | Osteogenesis | 1 | 2020 | 205 | 0.140 |
Why?
| | Cell Cycle Proteins | 3 | 1998 | 633 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2022 | 381 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2017 | 22 | 0.130 |
Why?
| | Lipoproteins | 3 | 2010 | 166 | 0.130 |
Why?
| | Body Fat Distribution | 1 | 2017 | 46 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 2 | 1997 | 323 | 0.130 |
Why?
| | Pericardium | 1 | 2017 | 59 | 0.120 |
Why?
| | Subcutaneous Fat | 1 | 2017 | 79 | 0.120 |
Why?
| | Sleep | 1 | 2024 | 895 | 0.120 |
Why?
| | Aorta | 2 | 2010 | 443 | 0.120 |
Why?
| | Heart Failure | 1 | 2010 | 2334 | 0.120 |
Why?
| | Phosphorylation | 3 | 2010 | 1721 | 0.120 |
Why?
| | Adiponectin | 2 | 2022 | 244 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 98 | 0.120 |
Why?
| | Hyperlipoproteinemias | 2 | 1987 | 5 | 0.120 |
Why?
| | Cell Cycle | 2 | 1996 | 600 | 0.110 |
Why?
| | Blood Vessels | 1 | 2017 | 167 | 0.110 |
Why?
| | Oxygen Consumption | 4 | 2021 | 721 | 0.110 |
Why?
| | Cell Division | 4 | 2009 | 758 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 277 | 0.110 |
Why?
| | Glycerol | 3 | 2012 | 90 | 0.110 |
Why?
| | Calcium | 2 | 2010 | 1197 | 0.100 |
Why?
| | Coronary Artery Disease | 2 | 2011 | 754 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 1994 | 62 | 0.100 |
Why?
| | Carcinoma, Small Cell | 1 | 1994 | 173 | 0.100 |
Why?
| | Body Composition | 2 | 2024 | 694 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2024 | 2080 | 0.090 |
Why?
| | Cholesterol | 4 | 2010 | 410 | 0.090 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 55 | 0.090 |
Why?
| | Liver | 2 | 2012 | 1916 | 0.090 |
Why?
| | Estrogens | 2 | 2026 | 368 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2010 | 4169 | 0.090 |
Why?
| | Lung Neoplasms | 2 | 1996 | 2679 | 0.090 |
Why?
| | Body Mass Index | 4 | 2026 | 2470 | 0.080 |
Why?
| | Caenorhabditis | 1 | 1990 | 4 | 0.080 |
Why?
| | Adipose Tissue | 2 | 2018 | 646 | 0.080 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 2 | 2024 | 217 | 0.080 |
Why?
| | Triglycerides | 8 | 2012 | 529 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2012 | 149 | 0.080 |
Why?
| | Creatinine | 2 | 2022 | 516 | 0.080 |
Why?
| | Rats, Inbred SHR | 1 | 2010 | 36 | 0.080 |
Why?
| | Embryo, Nonmammalian | 1 | 1990 | 171 | 0.080 |
Why?
| | Cohort Studies | 4 | 2018 | 6099 | 0.080 |
Why?
| | Receptors, LDL | 1 | 2010 | 53 | 0.080 |
Why?
| | Free Radical Scavengers | 1 | 2010 | 82 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.080 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 153 | 0.070 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 174 | 0.070 |
Why?
| | Age Factors | 4 | 2012 | 3372 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 800 | 0.070 |
Why?
| | Calcinosis | 1 | 2011 | 234 | 0.070 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 264 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 509 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2010 | 762 | 0.070 |
Why?
| | Counseling | 1 | 2012 | 407 | 0.070 |
Why?
| | Cyclin D1 | 2 | 2001 | 64 | 0.070 |
Why?
| | Propranolol | 3 | 1987 | 44 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 347 | 0.070 |
Why?
| | Phosphatidylcholine-Sterol O-Acyltransferase | 3 | 1985 | 8 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 618 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 440 | 0.060 |
Why?
| | Sex Characteristics | 3 | 2022 | 799 | 0.060 |
Why?
| | Mitochondria | 1 | 2014 | 1000 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 616 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2010 | 589 | 0.060 |
Why?
| | Cattle | 1 | 2009 | 948 | 0.060 |
Why?
| | Pregnanediol | 1 | 2026 | 23 | 0.060 |
Why?
| | Estrone | 1 | 2026 | 41 | 0.060 |
Why?
| | Energy Metabolism | 2 | 2024 | 936 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1987 | 252 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1994 | 1195 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1107 | 0.050 |
Why?
| | Menstrual Cycle | 1 | 2026 | 145 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 1990 | 1456 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2542 | 0.050 |
Why?
| | Heparin | 2 | 2022 | 249 | 0.050 |
Why?
| | Thermogenesis | 1 | 2024 | 45 | 0.050 |
Why?
| | Sex Factors | 4 | 2018 | 2136 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 1983 | 83 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 984 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 148 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2010 | 2791 | 0.050 |
Why?
| | Intra-Abdominal Fat | 2 | 2017 | 101 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2010 | 3153 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 361 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 15 | 0.050 |
Why?
| | Cold Temperature | 1 | 2024 | 207 | 0.050 |
Why?
| | Child | 6 | 2024 | 22979 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 344 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7173 | 0.040 |
Why?
| | Prolactin | 1 | 2022 | 88 | 0.040 |
Why?
| | Growth Hormone | 1 | 2022 | 91 | 0.040 |
Why?
| | Thyroid Hormones | 1 | 2022 | 69 | 0.040 |
Why?
| | Thyrotropin | 1 | 2022 | 120 | 0.040 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 202 | 0.040 |
Why?
| | Coronary Disease | 1 | 1983 | 382 | 0.040 |
Why?
| | Rats | 1 | 2010 | 5613 | 0.040 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 32 | 0.040 |
Why?
| | Muscle Strength | 1 | 2024 | 336 | 0.040 |
Why?
| | Emulsions | 1 | 2021 | 59 | 0.040 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.040 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 150 | 0.040 |
Why?
| | Primary Health Care | 1 | 2012 | 1759 | 0.040 |
Why?
| | Longevity | 1 | 2022 | 178 | 0.040 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 7 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 288 | 0.040 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 13 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 100 | 0.040 |
Why?
| | Leptin | 1 | 2022 | 249 | 0.040 |
Why?
| | Genetic Fitness | 1 | 2021 | 60 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2021 | 149 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 140 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 121 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3784 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2022 | 300 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 318 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 188 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1997 | 74 | 0.040 |
Why?
| | Animals | 4 | 2010 | 38410 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1997 | 106 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4604 | 0.040 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 51 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 193 | 0.040 |
Why?
| | Aging | 1 | 2010 | 1992 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 6041 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 617 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 6011 | 0.030 |
Why?
| | Cell Respiration | 1 | 2018 | 105 | 0.030 |
Why?
| | Aged | 4 | 2022 | 26514 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1998 | 143 | 0.030 |
Why?
| | CDC2-CDC28 Kinases | 1 | 1997 | 16 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1157 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2021 | 566 | 0.030 |
Why?
| | Capillary Resistance | 1 | 2017 | 4 | 0.030 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 48 | 0.030 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 21 | 0.030 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 28 | 0.030 |
Why?
| | Anthropometry | 1 | 2017 | 206 | 0.030 |
Why?
| | Adiposity | 2 | 2012 | 533 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 366 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 70 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 891 | 0.030 |
Why?
| | Microcirculation | 1 | 2017 | 142 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 703 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 313 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 14 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 1997 | 197 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 173 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 119 | 0.030 |
Why?
| | Progesterone | 1 | 1997 | 215 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1481 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 86 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 372 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2017 | 259 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 146 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2017 | 514 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 239 | 0.030 |
Why?
| | Hemoglobins | 1 | 2017 | 386 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1998 | 415 | 0.030 |
Why?
| | Mice | 2 | 2010 | 18491 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2021 | 1368 | 0.030 |
Why?
| | Blood Pressure | 2 | 2017 | 1785 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1998 | 584 | 0.030 |
Why?
| | Bone Density | 1 | 2017 | 493 | 0.020 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 203 | 0.020 |
Why?
| | Cytokines | 1 | 2021 | 2086 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2018 | 489 | 0.020 |
Why?
| | Risk | 2 | 1987 | 927 | 0.020 |
Why?
| | Protein Kinases | 1 | 1994 | 312 | 0.020 |
Why?
| | Risk Factors | 3 | 2012 | 11017 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 51 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 677 | 0.020 |
Why?
| | Autoradiography | 1 | 1990 | 66 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2012 | 147 | 0.020 |
Why?
| | Electrophoresis | 1 | 1990 | 31 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 59 | 0.020 |
Why?
| | Lipoproteins, HDL | 2 | 1981 | 104 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2133 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2012 | 538 | 0.020 |
Why?
| | Nucleotides | 1 | 1990 | 129 | 0.020 |
Why?
| | Health Expenditures | 1 | 2012 | 199 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 567 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 390 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1415 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7274 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 528 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1997 | 2625 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 453 | 0.020 |
Why?
| | Lung | 1 | 2001 | 4141 | 0.020 |
Why?
| | Transcription Factors | 1 | 1996 | 1747 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1868 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5476 | 0.020 |
Why?
| | Atenolol | 1 | 1987 | 8 | 0.020 |
Why?
| | Metoprolol | 1 | 1987 | 26 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2012 | 590 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1342 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 448 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 746 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2420 | 0.010 |
Why?
| | Diet | 1 | 2012 | 1284 | 0.010 |
Why?
| | Diet, Sodium-Restricted | 1 | 1983 | 39 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 8164 | 0.010 |
Why?
| | Smoking Prevention | 1 | 1983 | 167 | 0.010 |
Why?
| | Physical Exertion | 1 | 1983 | 205 | 0.010 |
Why?
| | Autoanalysis | 1 | 1981 | 8 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1983 | 1281 | 0.010 |
Why?
| | Lipoprotein Lipase | 1 | 1980 | 56 | 0.010 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 1979 | 30 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 1979 | 37 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1998 | 72 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1998 | 90 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 6164 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1266 | 0.010 |
Why?
| | Promegestone | 1 | 1997 | 9 | 0.010 |
Why?
| | Cyclin B | 1 | 1997 | 15 | 0.010 |
Why?
| | Cyclin A | 1 | 1997 | 17 | 0.010 |
Why?
| | Gonanes | 1 | 1997 | 23 | 0.010 |
Why?
| | Mifepristone | 1 | 1997 | 54 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1997 | 33 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1997 | 64 | 0.010 |
Why?
| | G1 Phase | 1 | 1997 | 65 | 0.010 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 1997 | 36 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1997 | 162 | 0.010 |
Why?
| | Drug Synergism | 1 | 1997 | 355 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1997 | 122 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 1983 | 1213 | 0.010 |
Why?
| | Cell Line | 1 | 2001 | 2832 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2001 | 1141 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2134 | 0.010 |
Why?
| | ErbB Receptors | 1 | 1997 | 638 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2886 | 0.010 |
Why?
| | United States | 1 | 2012 | 16313 | 0.010 |
Why?
| | Biomarkers | 1 | 2001 | 4351 | 0.000 |
Why?
| | Mutation | 1 | 1998 | 4130 | 0.000 |
Why?
| | Cholesterol Esters | 1 | 1985 | 7 | 0.000 |
Why?
| | Lipoproteins, VLDL | 1 | 1984 | 21 | 0.000 |
Why?
| | Injections, Intravenous | 1 | 1984 | 198 | 0.000 |
Why?
| | Microchemistry | 1 | 1981 | 19 | 0.000 |
Why?
| | Regression Analysis | 1 | 1984 | 1003 | 0.000 |
Why?
| | Capillaries | 1 | 1981 | 125 | 0.000 |
Why?
| | Germany, East | 1 | 1979 | 1 | 0.000 |
Why?
| | Occupational Medicine | 1 | 1979 | 14 | 0.000 |
Why?
| | Child, Preschool | 1 | 1981 | 12016 | 0.000 |
Why?
|
|
Schauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|